[ad_1]
Among the most pronounced names in recent months in the vaccine race, also that of the British multinational Johnson & Johnson. Today the good news of a phase change in the experimentation process of the English formula. After the setback in October after the side effects in a volunteer, the Janssen vaccine, the pharmaceutical company that belongs to the multinational JnJ, has officially passed to phase 3. This was announced by the British Health Minister Matt Hancock, thus confirming the excellent path also started for the third vaccine produced in the United Kingdom and currently passed in the last step of experimentation.
After the Oxford formula, Astrazeneca and Irbm from Pomezia and Novavax, now Janssen will also have to test the candidate vaccine on a larger scale of volunteers and hope to obtain a high percentage of efficacy. The phase started today will involve 7,000 volunteers in the UK and 23,000 in other countries. “It’s a very similar vaccine model to Oxford / AstraZeneca,” said Saul Faust, director of the laboratory coordinating the research project.
Phase 3 vaccines
Among the vaccines that are currently in phase three and most sought after to achieve the goal in a short time, Pfizer, Astrazeneca, Moderna and the two Russian ones, Sputnik V and EpiVacCorona. But not only. Here is the list of candidate formulas that are currently being tested in the later stage of the planned process.
- Ad26.CoV2.S (Johnson & Johnson)
- Ad5-nCoV (CanSino Biologics)
- AZD1222 (Astrazeneca)
- BNT162b2 (Pfizer)
- CoronaVac (Turkish Institutes of Health)
- Gam-COVID-Vac Lyo (Gamaleya Research Institute and Ministry of Health of Russia)
- MRNA 1273 (ModernaTX)
- Matrix-M1 ™ adjuvanted nanoparticle vaccine (Novavax)
- PROFISCOV (Butantan Institute)
- Vero cell (Elea Phoenix SA Laboratory, Beijing)
Read also:
[ad_2]
